August 16, 2011
Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis
SPARTANBURG, S.C., Aug. 16, 2011 /PRNewswire/ -- Femasys Inc. and Norgenix Pharmaceuticals, LLC today announced an agreement for exclusive distribution rights in the United States as well as US territories and military bases for Femasys' FemVue(TM) Saline-Air Device. This FDA cleared device is used to evaluate a woman's fallopian tubes with standard ultrasound, called a Sono HSG. Femasys Inc. is an emerging medical device developer of women's healthcare solutions. Norgenix Pharmaceuticals, LLC, a wholly owned subsidiary of the J M Smith Corporation, is a North American distributor with a world-class sales channel for medical device and pharmaceutical products in the women's health arena. Norgenix is licensed to sell, market, and distribute medical devices and prescription drug products in all 50 US states.
"Our agreement with Norgenix is anticipated to have an immediate and significant impact on our sales expansion efforts as we offer the market an advancement in diagnostic care for an infertile woman," stated Kathy Lee-Sepsick, President & CEO of Femasys Inc. "The Norgenix team is providing us with multiple ready-made relationships; we are excited to ramp our production to meet the numerous opportunities Norgenix has presented."The FemVue(TM) Saline-Air Device has been cleared by the FDA for use during diagnostic Sono HSG for fallopian tube evaluations. It creates a consistent alternating pattern of saline and air used as contrast allowing physicians to evaluate a woman's fallopian tubes with existing ultrasound equipment. With the FemVue pattern of saline and air, Sono HSG can be a reliable, cost-effective, convenient, and safe procedure performed quickly by a woman's gynecologist or infertility specialist in the office.
"We are pleased to announce our partnership with Femasys," stated Ken Couch, President of Norgenix Pharmaceuticals, LLC. "Femasys' FemVue device is an innovative product that perfectly aligns with our strategic mission to offer solutions to unmet needs in women's health."
"FemVue is an innovative solution in providing convenient and reliable evaluation of the fallopian tubes to the estimated 10 million women in the United States today, including those struggling with infertility or suffering from female fallopian tube disorders," stated Michael Rackley, COO & Senior Vice President of Norgenix Pharmaceuticals. "We are very optimistic about the potential for FemVue; we expect to expand the market rapidly."
ABOUT FEMASYS INC. | www.femasys.com
ABOUT NORGENIX | www.norgenixpharma.com
Sims Hammond, 864.580.2350, [email protected]
SOURCE Norgenix Pharmaceuticals, LLC